RARE vs RCKT Stock Comparison
Compare RARE and RCKT across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between RARE and RCKT?
RARE leads the current stock comparison as Ultragenyx Pharmaceutical Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Ultragenyx Pharmaceutical Inc. vs Rocket Pharmaceuticals, Inc.
RARE leads
RARE leads by 5 AIQ points, primarily on Quality, and the lead has widened from 0 points over 30 sessions.
Fragile: 3 of 5 evidence groups support RARE, its lead is widening, and its current signal state is conflicted.
Ultragenyx Pharmaceutical Inc.
Rocket Pharmaceuticals, Inc.
The Algovestiq AIQ Score currently favors RARE over RCKT, 43 versus 38 as of Sep 11, 2026. RARE's advantage is driven primarily by stronger quality, while RCKT holds the stronger risk resilience profile. RARE also shows the weaker technical structure relative to its 50-day moving average. 3 of 5 covered evidence groups favor RARE today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 5 points. RARE lead: Strengthening — the AIQ differential moved from 0 to 5 points over 30 sessions.
Compare Ultragenyx Pharmaceutical Inc. and Rocket Pharmaceuticals, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare RARE and RCKT against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality64 vs 29RARE +35
- Risk Resilience21 vs 48RCKT +27
- Momentum21 vs 42RCKT +21
3 of 5 evidence groups favor RARE. RARE’s edge is concentrated in quality; RCKT keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
No factor moved materially.
New signals
- 52-Week Low Proximity — bearish, risk, long horizon (1.0%)
Largest factor move: Momentum -19
New signals
- Downtrend Structure Active — bearish, trend, long horizon
- MACD Bearish Crossover — bearish, momentum, short horizon
The lead changed hands: RARE moved ahead of RCKT in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — RARE and RCKT both carry a full feed there.
The central trade-off
RARE (Ultragenyx Pharmaceutical Inc.): the stronger current systematic profile, led by quality.
RCKT (Rocket Pharmaceuticals, Inc.): the counter-case, on risk resilience, momentum, technicals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
RARERARE on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
RARERARE on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
RCKTRCKT on the Momentum factor, by 21 points.
Lower downside
RCKTRCKT on Risk Resilience, by 27 points.
Analyst upside
RARERARE on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | RARE | RCKT | Note |
|---|---|---|---|
| Implied upside to target | +154.9% | +49.3% | RARE has more room |
| Target dispersion | +183.8% | 0% | Lower is tighter analyst agreement |
| Consensus | Buy | Hold | Context, not a primary driver |
| Analysts covering | 12 | 1 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 5 covered evidence groups favor RARE. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | RARE | 43 vs 38 |
| Fundamentals | RARE | EPS growth 51.1% vs 3.6%; TTM ROE 3.9% vs -5.8% |
| Valuation | Not covered | Not covered |
| Technicals | RCKT | Price vs 50-day -46.4% vs -6.2%; vs 200-day -44% vs -3% |
| Risk Resilience | RCKT | Risk Resilience 21 vs 48 |
| Analyst expectations | RARE | Target upside 154.9% vs 49.3% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of RARE and RCKT and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 5 points. (argues the conclusion is provisional)
- The leader's advantage has been widening. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on RARE.
How the comparison changed
119 daily snapshots · May 4 – Sep 10RARE lead: Strengthening — the AIQ differential moved from 0 to 5 points over 30 sessions.
- Today
- RARE +5
- 43 vs 38
- 7 sessions ago
- RCKT +6
- 43 vs 49
- 30 sessions ago
- Level
- 49 vs 49
- 90 sessions ago
- RARE +7
- 58 vs 51
The lead changed hands 4 times in this window, most recently on Sep 10 when RARE moved ahead of RCKT.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 3 bearish / 1 neutral, conflicted
- Golden Cross Active — bullish, trend, long horizon (3.69%)
- Keltner Channel Breakdown — bearish, volatility, short horizon
- RSI Oversold - Potential Bounce — bullish, momentum, short horizon
1 bullish / 3 bearish / 1 neutral, conflicted
- Death Cross Active — bearish, trend, long horizon (0.47%)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Downtrend Structure Active — bearish, trend, long horizon
RARE leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.69%, AIQ 0 points).
Price and the AIQ Score both moved down over the latest session (price -3.74%, AIQ -6 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1RCKT closes the Quality gap — currently 35 points behind, the largest single contributor to RARE's edge.
- 2RCKT's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3RARE's conflicting signal state resolves bearish — it currently carries 2 bullish and 3 bearish rules at once.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
RARE leads on balance| Metric | RARE | RCKT |
|---|---|---|
| Revenue growth (YoY) | 57.4% | 0% |
| EPS growth (YoY) | 51.1% | 3.6% |
| Gross margin | 83.1% | 0% |
| Operating margin | -73.8% | 0% |
| Return on equity (TTM) | 3.9% | -5.8% |
| Debt to equity | -4.13 | 0.07 |
Performance
RCKT leads 6 of 6 windows| Metric | RARE | RCKT |
|---|---|---|
| 1 week (5 sessions) | -41.1% | -9.8% |
| 1 month (20 sessions) | -43.4% | 2.1% |
| 3 months (63 sessions) | -37.3% | 33.8% |
| 6 months (126 sessions) | -35.2% | -27.8% |
| Year to date | -37.4% | -0.9% |
| 1 year (252 sessions) | -54.3% | 6.7% |
Technicals
RCKT has the stronger structure| Metric | RARE | RCKT |
|---|---|---|
| RSI (14) | 18.1 | 50 |
| ADX (14) | 27.2 | 21.7 |
| Price vs 50-day | -46.4% | -6.2% |
| Price vs 200-day | -44% | -3% |
| Volatility (1M, annualized) | 159.7% | 64% |
Risk
RCKT is the more resilient| Metric | RARE | RCKT |
|---|---|---|
| Beta | 1.19 | 1.93 |
| Sharpe ratio | -0.52 | 0.41 |
| Sortino ratio | -0.5 | 0.73 |
| Max drawdown | -60.8% | -50.9% |
| Current drawdown | -60.6% | -34.3% |
| Annualized volatility | 80.5% | 71.5% |
| Value at risk (95%) | -4.3% | -5.8% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, RARE or RCKT?
On the Algovestiq AIQ Score, RARE is the stronger of the two as of Sep 11, 2026, scoring 43 against RCKT's 38. The edge comes from quality. RCKT is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is RARE or RCKT the better buy right now?
RARE carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Fragile — 3 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 5 points. Treat the lead as provisional.
Why does the AIQ Score favor RARE over RCKT?
The composite weights Quality, Value, Momentum and Risk Resilience. RARE leads Quality by 35 points; RCKT leads Risk Resilience by 27 points; RCKT leads Momentum by 21 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, RARE or RCKT?
Analyst price targets imply +154.9% upside for RARE and +49.3% for RCKT, so the Street currently favors RARE. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, RARE or RCKT?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, RARE or RCKT?
RARE on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, RARE or RCKT?
RCKT on the Momentum factor, by 21 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, RARE or RCKT?
RCKT is the more resilient of the two, so the other name carries the higher downside risk. RCKT on Risk Resilience, by 27 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is RARE more profitable than RCKT?
RARE leads on the comparable margin measures — gross margin 83.1% vs 0%; operating margin -73.8% vs 0%; ttm roe 3.9% vs -5.8%.
Is RARE's lead over RCKT getting stronger or weaker?
RARE lead: Strengthening — the AIQ differential moved from 0 to 5 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands 4 times in that window, most recently on 2026-09-10, when RARE moved ahead of RCKT.
What would change the RARE vs RCKT verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: RCKT closes the Quality gap — currently 35 points behind, the largest single contributor to RARE's edge; RCKT's Death Cross Active resolves — a bearish trend rule currently active against it; RARE's conflicting signal state resolves bearish — it currently carries 2 bullish and 3 bearish rules at once; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about RARE and RCKT?
RARE: 2 bullish / 3 bearish / 1 neutral, conflicted. RCKT: 1 bullish / 3 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on RARE is Golden Cross Active (bullish, long horizon). On RCKT it is Death Cross Active (bearish, long horizon).
Compare RARE and RCKT with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.